Načítá se...
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
Progressive fibrosing interstitial lung diseases (ILDs) involve similar pathophysiological processes, indicating the potential for common approaches to treatment. Nintedanib (Ofev(®)), an intracellular tyrosine kinase inhibitor (TKI) with antifibrotic properties, was one of the first drugs approved...
Uloženo v:
| Vydáno v: | Drugs |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer International Publishing
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8163683/ https://ncbi.nlm.nih.gov/pubmed/33765296 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-021-01487-0 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|